Formulation Development
SIRION Biotech & Sanofi Join Forces to Develop Gene Therapies for Multiple Life-Threatening Disorders
SIRION Biotech GmbH recently announced it signed a license and collaboration agreement with Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize….
Catalent to Acquire Delphi Genetics & Launch US Plasmid Manufacturing Site to Establish Global pDNA Development & Manufacturing Capabilities
Catalent and Delphi Genetics recently announced they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics. Catalent is also….
Halberd Collaborates With GreenBioAZ for the Development of Its Patent Pending Radio Frequency Technology
Halberd Corporation has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent-pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease pathogens. The methodology…
Intra-Cellular Therapies Applies for FDA Approval of Bipolar Depression Treatment
Intra-Cellular Therapies, Inc. recently announced it has submitted supplemental New Drug Applications (sNDAs) to the US FDA for two indications for CAPLYTA (lumateperone): 1) as…
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer
Celsion Corporation recently announced that it has received Fast Track designation from the US FDA for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy currently in Phase…
Catalent Announces Commercial Supply Agreement With Aurinia Pharmaceuticals
Catalent recently announced it recently signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals, a biopharmaceutical company focused on delivering therapies to treat targeted patient…
Oral Delivery of Hydrophilic Macromolecules: Lipid-Based Nanocarriers as Key to Success
This LIVE event has already taken place CLICK HERE to access the recorded version of this event and receive a copy of the presentation. Join…
SCYNEXIS Announces Licensing Agreement & Strategic Partnership With Hansoh Pharma
SCYNEXIS, Inc. recently announced it has entered into a licensing agreement and strategic partnership with Hansoh Pharmaceutical Group Company Limited…..
Biomunex Pharmaceuticals Signs Strategic License & Co-development Agreement With Onward Therapeutics
Biomunex Pharmaceuticals and Onward Therapeutics SA recently announced the signing of a strategic exclusive worldwide license and co-development agreement for a proprietary….
Altimmune Announces FDA Clearance of Single-Dose, Needle-Free, Intranasal COVID-19 Vaccine Candidate
Altimmune, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID….
Lonza Expands Solid Form Screening Services for Accelerated Development of Small Molecule Drugs
Lonza recently announced an expansion of its solid form selection services based at its Bend, OR, site. The increased service capabilities and dedicated team complement…
Synairgen Announces Dosing Has Commenced With Its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients
Synairgen plc recently announced that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase 2/3 trial evaluating patients with…
Progenity Initiates Safety & Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases
Progenity, Inc. recently announced the initiation of a clinical study for their Drug Delivery System (DDS) capsule, an ingestible and self-guided drug delivery device. The…
Enlivex Announces Issuance of New US Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis & GvHD Using Allocetra Immunotherapy
Enlivex Therapeutics Ltd. recently announced the US Patent and Trademark Office has issued US Patent No. 10,927,343 covering Allocetra, the company’s immunotherapy product candidate. The…
Artelo Biosciences Announces Positive Pre-Clinical Data Associated With Proprietary CBD Cocrystal
Artelo Biosciences, Inc. recently announced Saoirse O’Sullivan, PhD, Professor of Pharmacology and Scientific Advisor to Artelo, along with Ryan Maguire and Dr. Timothy England of…
Maravai LifeSciences Expands Its Intellectual Property Portfolio
Maravai LifeSciences, Inc. recently announced the United States Patent and Trademark Office has issued a new patent, United States Patent No. 10,913,768, to the company’s TriLink Biotechnologies subsidiary…..
Quotient Sciences Acquires UK-Based Contract Development & Manufacturing Organization
Quotient Sciences, the drug development and manufacturing accelerator, recently announced it has acquired Arcinova, the UK-based multiservice contract development and….
Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor
Celon Pharma S.A. recently announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in….
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDAr as First-line Treatment for HPV+ Recurrent/Metastatic Head & Neck Cancer
Cue Biopharma, Inc. recently announced the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck's anti-PD-1…
OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines & Therapeutics
OliX Pharmaceuticals, Inc. recently announced the establishment of mCureX Therapeutics, Inc., a subsidiary focused on the research and development of messenger RNA (mRNA) vaccines and…
